Categoría: Geovanny Vicente

WASHINGTON, Dec. 28, 2020 /PRNewswire-HISPANIC PR WIRE/ — «E-cigarette sales are driving a youth tobacco tipping point. But we now have new tools to protect youth and support parents frustrated by the targeting of their children and the ease of purchasing e-cigarettes online,» said Jane L. Delgado, PhD, MS, President and CEO of the National Alliance for Hispanic Health, the nation’s leading Hispanic health advocacy group.

Yesterday, with signing of the 2021 Omnibus Appropriations Bill, The Preventing Online Sales of E-Cigarettes to Children Act becoming law. The new law will apply the same safeguards already in place for traditional cigarettes to online sales of electronic cigarettes and vapor products, including age ID requirements.

With vaping linked to substantially increased risk of COVID-19 among teenagers and young adults, it is more important than ever to have all tools necessary to reverse rates of vaping among youth. E-cigarettes are the most commonly used tobacco product among high school and middle school youth, including Hispanic youth. Online sales are a critical component of reversing e-cigarette use for youth as online and mobile advertising platforms are popular places for e-cigarette advertising, including ads for flavored products appealing to youth, and a majority (63.2%) of internet vendors could not effectively verify age or made no attempt at all to verify.

«We applaud Senators Feinstein (D-CA) and Cornyn (R-TX) in the Senate and Reps. Rosa DeLauro (D-CT) and Kelly Armstrong (R-ND) in the House for their introduction and tireless work to bring about passage of this bipartisan legislation to protect children and families,» concluded Dr. Delgado.

About the National Alliance for Hispanic Health (The Alliance)
The Alliance is the nation’s foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all. For more information visit us at www.healthyamericas.org

SOURCE National Alliance for Hispanic Health

WASHINGTON, Dec. 28, 2020 /PRNewswire/ — «E-cigarette sales are driving a youth tobacco tipping point. But we now have new tools to protect youth and support parents frustrated by the targeting of their children and the ease of purchasing e-cigarettes online,» said Jane L. Delgado, PhD, MS, President and CEO of the National Alliance for Hispanic Health, the nation’s leading Hispanic health advocacy group.

Yesterday, with signing of the 2021 Omnibus Appropriations Bill, The Preventing Online Sales of E-Cigarettes to Children Act becoming law. The new law will apply the same safeguards already in place for traditional cigarettes to online sales of electronic cigarettes and vapor products, including age ID requirements.

With vaping linked to substantially increased risk of COVID-19 among teenagers and young adults, it is more important than ever to have all tools necessary to reverse rates of vaping among youth. E-cigarettes are the most commonly used tobacco product among high school and middle school youth, including Hispanic youth. Online sales are a critical component of reversing e-cigarette use for youth as online and mobile advertising platforms are popular places for e-cigarette advertising, including ads for flavored products appealing to youth, and a majority (63.2%) of internet vendors could not effectively verify age or made no attempt at all to verify.

«We applaud Senators Feinstein (D-CA) and Cornyn (R-TX) in the Senate and Reps. Rosa DeLauro (D-CT) and Kelly Armstrong (R-ND) in the House for their introduction and tireless work to bring about passage of this bipartisan legislation to protect children and families,» concluded Dr. Delgado.

About the National Alliance for Hispanic Health (The Alliance)
The Alliance is the nation’s foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all. For more information visit us at www.healthyamericas.org

View original content:http://www.prnewswire.com/news-releases/national-alliance-for-hispanic-health-praises-enactment-of-the-preventing-online-sales-of-e-cigarettes-to-children-act-301198849.html

SOURCE National Alliance for Hispanic Health

TEL-AVIV, Israel, Dec. 28, 2020 /PRNewswire/ — Ellomay Capital Ltd. (NYSE American: ELLO) (TASE: ELLO) («Ellomay« or the «Company«), a renewable energy and power generator and developer of renewable energy and power projects in Europe and Israel, today reported its unaudited financial results for the three and nine months ended September 30, 2020.

Financial Highlights

• Revenues were approximately €6.8 million for the nine months ended September 30, 2020, compared to approximately €15.4 million for the nine months ended September 30, 2019. The decrease in revenues is mainly due to the sale of ten Italian indirectly wholly-owned subsidiaries of the Company, which held twelve photovoltaic plants in Italy with an aggregate installed capacity of approximately 22.6 MWp (the «Italian PV Portfolio«), consummated during December 2019. A small portion of the decrease in revenues for the nine months ended September 30, 2020 resulted from the decrease in demand and prices of the European electricity markets due to the Covid-19 crisis, partially offset by increase in revenues in one of the Company’s biogas facilities in the Netherlands resulting from increased operational efficiency.
• Operating expenses were approximately €3.4 million for the nine months ended September 30, 2020, compared to approximately €5 million for the nine months ended September 30, 2019. The decrease in operating expenses is mainly attributable to the sale of the Italian PV Portfolio, to increased operational efficiency of the Company’s Waste-to-Energy projects in the Netherlands and to insurance reimbursement in connection with the storm damages in one of our biogas facilities in the Netherlands that reduced operating expenses. Depreciation expenses were approximately €2.2 million for the nine months ended September 30, 2020, compared to approximately €4.7 million for the nine months ended September 30, 2019. The decrease reflects the sale of the Italian PV Portfolio.
• Project development costs were approximately €3 million for the nine months ended September 30, 2020, compared to approximately €3.5 million for the nine months ended September 30, 2019. The decrease in project development costs is mainly due to a decrease in consultancy expenses in connection with the project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel, partially offset by consultancy expenses in connection with the development of photovoltaic projects in Italy.
• General and administrative expenses were approximately €3.3 million for the nine months ended September 30, 2020, compared to approximately €2.9 million for the nine months ended September 30, 2019. The increase is mostly due to D&O liability insurance costs.
• Company’s share of profits of equity accounted investee, after elimination of intercompany transactions, was approximately €1.9 million for the nine months ended September 30, 2020, compared to approximately €2.4 million in the nine months ended September 30, 2019. The decrease in the Company’s share of profit of equity accounted investee is mainly attributable to lower revenues of Dorad Energy Ltd. («Dorad«) as a result of a decrease in the TAOZ tariffs and a decrease in the production tariff, partially offset by lower financing expenses incurred by Dorad. for the period as a result of the CPI indexation of loans from banks.
• Financing expenses, net was approximately €2.3 million for the nine months ended September 30, 2020, compared to approximately €4.6 million for the nine months ended September 30, 2019. The decrease in financing expenses, net, was mainly due to income recorded in connection with the reevaluation of the Company’s derivative transactions and revaluation of a loan provided to U. Dori Energy Infrastructures Ltd.in the aggregate amount of approximately €1.5 million during the nine months ended September 30, 2020, compared to approximately €1 million during the nine months ended September 30, 2019, and a decrease in financing expenses of approximately €1.7 million resulting from the early repayment of the Company’s Series A Debentures and the sale of the Italian PV Portfolio, including all related project finance.
• Taxes on income was approximately €0.2 million for the nine months ended September 30, 2020, compared to taxes on income of approximately €0.9 million for the nine months ended September 30, 2019. The decrease in tax expenses is mainly attributable to the sale of the Italian PV Portfolio and deferred tax income related to the operations of the project company constructing a photovoltaic plant with a peak capacity of 300MW in Spain, in which the Company holds 51%.
• Net loss was approximately €5.7 million for the nine months ended September 30, 2020, compared to approximately €3.8 million for the nine months ended September 30, 2019.
• Total other comprehensive loss was approximately €3.1 million for the nine months ended September 30, 2020, compared to a profit of approximately €13.8 million for the nine months ended September 30, 2019. The change was mainly due to changes in fair value of cash flow hedges and from foreign currency translation differences on NIS denominated operations, as a result of fluctuations in the euro/NIS exchange rates.
• Total comprehensive loss was approximately €2.6 million for the nine months ended September 30, 2020, compared to income of approximately €10 million for the nine months ended September 30, 2019.
• EBITDA loss was approximately €(1) million for the nine months ended September 30, 2020, compared to EBITDA of approximately €6.4 million for the nine months ended September 30, 2019.
• Net cash used in operating activities was approximately €2.2 million for the nine months ended September 30, 2020, compared to net cash provided from operating activities of approximately €4.3 million for the nine months ended September 30, 2019. The decrease in net cash from operating activities is mainly attributable to the sale of the Italian PV Portfolio.
• On July 20, 2020, the Company issued 450,000 ordinary shares to several Israeli qualified investors in a private placement undertaken in accordance with Regulation S of the Securities Act of 1933, as amended. The price per share was set at NIS 70.5 (approximately €18.9). The gross proceeds to the Company in connection with the private placement amounted to approximately NIS 31.7 million (approximately €8.2 million).
• On October 26, 2020, the Company completed a public offering in Israel of Series C Debenture and a of a new series of options, tradable on the Tel Aviv Stock Exchange, to purchase the Company’s ordinary shares at an exercise price per share of NIS 150 (the «Series 1 Options«). The Company issued an aggregate principal amount of NIS 154 million (approximately €38.3 million based on the exchange rate as of September 30, 2020) of its Series C Debentures and 385,000 Series 1 Options. The gross proceeds from the offering amounted to approximately NIS 164.2 million (approximately €40.8 million based on the exchange rate as of September 30, 2020).
• On December 1, 2020 the Company acquired all issued and outstanding shares of Groen Gas Gelderland B.V. («GG Gelderland«) through its wholly-owned subsidiary, Ellomay Luxembourg Holdings S.à.r.l. («Ellomay Luxembourg«) The Company paid €1.568 million for the shares and the repayment of shareholder loans. An additional shareholder loan of approximately €5.9 million was granted to GG Gelderland by Ellomay Luxembourg on December 1, 2020. The previous owners are entitled to receive an additional amount from the Dutch Government for subsidy payments. This amount is estimated at €0.493 million, but will be determined and paid before June 2021. The Company has no liability to compensate the previous owners if the Dutch government pays less than the estimated amount. GG Gelderland owns an operating anaerobic digestion plant in Gelderland, the Netherlands, with a permit that enables it to produce approximately 7.5 million Nm3 per year. The actual production capacity of the plant is approximately 9.5 million Nm3 per year.
• As of December 1, 2020 , the Company held approximately €92.7 million in cash and cash equivalents, approximately €2.2 million in marketable securities and approximately €9.8 million in restricted short-term and long-term cash and marketable securities.
• As noted above, the revenues for the nine months ended September 30, 2020 were impacted by the decrease in demand and market prices of electricity in Spain resulting from the Covid-19 pandemic.  Although the Company’s operations have not thus far been materially adversely affected by the pandemic, the Company’s operations, including, but not limited to, its results of operations, ability to raise capital and ability to develop new projects, may in the future be adversely affected by the implications of the spread of Covid-19 in Israel, Europe and worldwide. These potential affects could last until a vaccine or successful treatment plan are developed and implemented worldwide.

CEO Review

Ran Fridrich, CEO and a board member of the Company, provided the following CEO review:

«The Company continued coping with the challenges posed by the Covid-19 pandemic during the three months ended September 30, 2020, and despite such challenges, the Company continues in full steam advancing its development plans in Italy (P.V), Spain (P.V) and the Netherland (Biogas), and advancing towards grid connection of project Talasol (300 MW P.V in Spain).

The results of the third quarter were in-line with the Company’s expectations, reflecting the effects of the Company’s PV Italian portfolio sale on December 2019. The upcoming commencement of operations of Talasol will more than compensate for this loss of income.

During December 2020 the Company successfully finalized the acquisition of the Gelderland biogas project in the Netherlands, doubling the Company’s biogas capacity and enabling it to improve the efficiency and utilize the benefits provided by the size of the facilities and the expertise of its Dutch and Israeli teams. The third quarter also reflects the improvements and increased efficiency of the Company’s biogas facilities in the Netherlands, which are working in line with the Company’s production targets and business plan.

Last week Hemi Raphael, who was an active Board member of the Company from 2006 until recently, passed away. Hemi was instrumental in the success and development of the Company throughout the years, and contributed to every aspect of the Company’s business and operations, including the Company’s holdings in Dorad, the acquisition of the Company’s operating assets and the development of the Company’s long-term strategy. He will be greatly missed.»

Use of NON-IFRS Financial Measures 

EBITDA is a non-IFRS measure and is defined as earnings before financial expenses, net, taxes, depreciation and amortization. The Company presents this measure in order to enhance the understanding of the Company’s historical financial performance and to enable comparability between periods. While the Company considers EBITDA to be an important measure of comparative operating performance, EBITDA should not be considered in isolation or as a substitute for net income or other statement of operations or cash flow data prepared in accordance with IFRS as a measure of profitability or liquidity. EBITDA does not take into account the Company’s commitments, including capital expenditures, and restricted cash and, accordingly, is not necessarily indicative of amounts that may be available for discretionary uses. Not all companies calculate EBITDA in the same manner, and the measure as presented may not be comparable to similarly-titled measures presented by other companies. The Company’s EBITDA may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. A reconciliation between results on an IFRS and non-IFRS basis is provided in the last table of this press release.

About Ellomay Capital Ltd. 

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol «ELLO». Since 2009, Ellomay Capital focuses its business in the renewable energy and power sectors in Europe and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy and Spain, including:

• Approximately 7.9MW of photovoltaic power plants in Spain and a photovoltaic power plant of approximately 9 MW in Israel;
• 9.375% indirect interest in Dorad Energy Ltd., which owns and operates one of Israel’s largest private power plants with production capacity of approximately 860MW, representing about 6%-8% of Israel’s total current electricity consumption;
• 51% of Talasol, which is involved in a project to construct a photovoltaic plant with a peak capacity of 300MW in the municipality of Talaván, Cáceres, Spain;
• Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million (with a license to produce 7.5 million) Nm3 per year, respectively;
• 75% of Ellomay Pumped Storage (2014) Ltd. (including 6.67% that are held by a trustee in trust for us and other parties), which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel.

For more information about Ellomay, visit http://www.ellomay.com.

Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements.  The use of certain words, including the words «estimate,» «project,» «intend,» «expect,» «believe» and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including the impact of the Covid-19 pandemic on the Company’s operations and projects, including in connection with steps taken by authorities in countries in which the Company operates, changes in the market price of electricity and in demand, regulatory changes, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, and technical and other disruptions in the operations or construction of the power plants owned by the Company. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:
Kalia Weintraub 
CFO
Tel: +972 (3) 797-1111
Email: kaliaw@ellomay.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Information for the Company’s Debenture Holders

Pursuant to the Deeds of Trust governing the Company’s Series B and C Debentures (together, the «Debentures«), the Company is required to maintain certain financial covenants. For more information, see Item 5.B of the Company’s Annual Report on Form 20-F submitted to the Securities and Exchange Commission on April 7, 2020.

Net Financial Debt

As of September 30, 2020, the Company did not have a Net Financial Debt, as the calculation of Net Financial Debt (as such term is defined in the Deeds of Trust of the Company’s Debentures), resulted in a negative amount (i.e., an excess of assets over liabilities) of approximately €(19.3) million (consisting of approximately €194.1 million of short-term and long-term debt from banks and other interest bearing financial obligations and approximately €43.1 million in connection with the Series B Debentures issuance (in March 2017) and the Series C Debentures issuance (in July 2019), net of approximately €62.7 million of cash and cash equivalents, short-term deposits and marketable securities and net of approximately €193.8* million of project finance and related hedging transactions of the Company’s subsidiaries).

* The project finance amount deducted from the calculation of Net Financial Debt includes project finance obtained from various sources, including financing entities and the minority shareholders in project companies held by the Company (provided in the form of shareholders’ loans to the project companies).

Information for the Company’s Series B Debenture Holders

The following is an internal pro forma consolidated statement of financial position of the Company as at September 30, 2020. This information is required under the Series B Deed of Trust in connection with the adoption of IFRS 16 «Leases» by the Company and provides the consolidated statement of financial position of the Company as of the date set forth below after elimination of the effects of adoption of IFRS 16. Based on the pro forma statement of financial position, the ratio of the Company’s equity (which the Company calculated in line with the definition of Balance Sheet Equity in the Series B Deed of Trust) to balance sheet as at September 30, 2020 was 36.8%.

 

 

Information for the Company’s Series C Debenture Holders

The Deed of Trust governing the Company’s Series C Debentures includes an undertaking by the Company to maintain certain financial covenants, whereby a breach of such financial covenants for two consecutive quarters is a cause for immediate repayment. As of September 30, 2020, the Company was in compliance with the financial covenants set forth in the Series C Deed of Trust as follows: (i) the Company’s shareholders’ equity was €126.3 million and (ii) the Company did not have a Net Financial Debt. In the event the Company does not have a Net Financial Debt the calculation of the two covenants that are based on Net Financial Debt (i.e., the ratio of the Company’s Net Financial Debt to the Company’s CAP, Net (defined as the Company’s consolidated shareholders’ equity plus the Net Financial Debt) and the ratio of the Company’s Net Financial Debt to the Company’s Adjusted EBITDA⁽¹⁾), becomes irrelevant and the Company is therefore in compliance with such covenants.

^{______________________________________________}

⁽¹⁾ The term «Adjusted EBITDA» is defined in the Series C Deed of Trust as earnings before financial expenses, net, taxes, depreciation and amortization, where the revenues from the Company’s operations, such as the Talmei Yosef project, are calculated based on the fixed asset model and not based on the financial asset model (IFRIC 12), and before share-based payments. The Series C Deed of Trust provides that for purposes of the financial covenant, the Adjusted EBITDA will be calculated based on the four preceding quarters, in the aggregate. The Adjusted EBITDA is presented in this press release as part of the Company’s undertakings towards the holders of its Series C Debentures. For a general discussion of the use of non-IFRS measures, such as EBITDA and Adjusted EBITDA see above under «Use of NON-IFRS Financial Measures.»

The following is a reconciliation between the Company’s profit and the Adjusted EBITDA for the four-quarter period ended September 30, 2020*:

___________________________________

* As noted above, the Company is in compliance with the covenant with respect to the ratio of Net Financial Debt to Adjusted EBITDA as the Company does not have a Net Financial Debt as of the end of the period. Therefore, the Adjusted EBITDA calculation above is provided for convenience and consistency purposes only.

 

 

 

View original content:http://www.prnewswire.com/news-releases/ellomay-capital-reports-results-for-the-three-and-nine-months-ended-september-30-2020-301198734.html

SOURCE Ellomay Capital Ltd

BETHESDA, Maryland, 28 de diciembre de 2020 /PRNewswire-HISPANIC PR WIRE/ — Los Institutos Nacionales de Salud han otorgado ocho subvenciones de investigación para desarrollar enfoques que sirvan para identificar a los niños que tienen alto riesgo de desarrollar el síndrome inflamatorio multisistémico pediátrico (MIS-C), un efecto secundario poco común y grave de la COVID-19, o de estar expuestos al virus que lo causa. Se proporcionarán hasta $20 millones para los proyectos durante cuatro años, dependiendo de la disponibilidad de los fondos.

«Estas subvenciones remarcan el compromiso de los NIH para identificar a los niños en riesgo de padecer el MIS-C, quienes informarán el desarrollo de las intervenciones para mejorar sus resultados de salud», dijo Diana Bianchi, MD, directora del Instituto Nacional de Salud Infantil y Desarrollo Humano Eunice Kennedy Shriver (NICHD) de los NIH. El NICHD y el Instituto Nacional del Corazón, los Pulmones y la Sangre lideran el esfuerzo de todos los NIH para comprender el espectro de las enfermedades pediátricas del SARS-CoV-2.

En la mayoría de los casos, los niños expuestos o infectados con el SARS-COV-2, el virus que causa la COVID-19, no desarrollan ningún síntoma o solo desarrollan una enfermedad leve. Algunos niños se enferman gravemente en el momento de la infección. Otros, que inicialmente no tienen síntomas, pueden desarrollar el MIS-C, una afección grave, a veces fatal, que se caracteriza por producir la inflamación de uno o más órganos, incluidos el corazón, los pulmones, los riñones, el cerebro, la piel, los ojos y el tracto gastrointestinal.

Las subvenciones de los NIH financiarán los estudios que inscriban a niños de diversos orígenes geográficos, raciales y étnicos en 30 estados de los EE. UU., Canadá, el Reino Unido y América del Sur. Los estudios explorarán cómo los factores genéticos, inmunes, virales, ambientales y otros influyen en la severidad con la que se desarrolla la COVID-19 en los niños y las posibilidades de que esta progrese y se presente el MIS-C y otras complicaciones a largo plazo. Las subvenciones provienen de la iniciativa Predicción de la Gravedad de la Enfermedad Inflamatoria Asociada a un Virus en Niños con Diagnósticos de Laboratorio e Inteligencia Artificial (PreVAIL kIds) de los NIH. Estas subvenciones son parte del programa Radical (RADx-rad) de la iniciativa Aceleración Rápida del Diagnóstico (Radx) y respaldan los enfoques nuevos y no tradicionales, y los usos reinventados de herramientas existentes para abordar las brechas en la toma de pruebas y la vigilancia de la COVID-19.

Las nuevas subvenciones evaluarán los genes, las proteínas del sistema inmunológico y otros biomarcadores. Además, examinarán cómo el virus interactúa con el cuerpo y cómo responde el sistema inmunológico. Estos estudios se basarán en la inteligencia artificial y el aprendizaje automático para interpretar los datos que se adquieran y para comprender los factores de riesgo que subyacen a la gravedad de la COVID-19 y el MIS-C.

La siguiente es una lista de los adjudicatarios y los nombres de los proyectos:

• Jane C. Burns, Universidad de California, San Diego
  Diagnóstico y predicción del riesgo en niños con enfermedades relacionadas con el SARS-CoV-2
• Cedric Manlhiot, Universidad Johns Hopkins, Baltimore
  Un enfoque de la ciencia de datos para identificar y manejar el MIS-C asociado con la infección por SARS-CoV-2 y la enfermedad de Kawasaki en pacientes pediátricos
• Ananth V. Annapragada, Escuela de Medicina de Baylor, Houston
  Evaluación por medio de la inteligencia artificial de los riesgos de la COVID-19 en niños
• Audrey R. Odom John, Hospital de Niños de Filadelfia
  Diagnóstico del MIS-C en niños febriles
• Usha Sethuraman, Universidad Central de Michigan, Mount Pleasant
  Indicadores de gravedad que integran la transcriptómica y proteómica salival con inteligencia de redes neuronales múltiples en la infección por SARS-CoV2 en niños
• Juan C. Salazar, Centro Médico Infantil de Connecticut, Hartford
  Identificación de las firmas de biomarcadores de valor pronóstico para el MIS-C
• Charles Yen Chiu, Universidad de California, San Francisco
  Descubrimiento y validación clínica de biomarcadores del huésped de la gravedad de la enfermedad y el MIS-C con la COVID-19
• Lawrence Kleinman, Escuela de Medicina Rutgers Robert Wood Johnson, Nuevo Brunswick, Nueva Jersey
  Red de redes COVID-19 que amplían los enfoques clínicos y traslacionales para predecir enfermedades graves en los niños

Referencia

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds). 2020.

###

Acerca de la iniciativa Aceleración Rápida del Diagnóstico (RADx^SM): La iniciativa RADx se lanzó el 29 de abril de 2020 para acelerar la innovación en el desarrollo, la comercialización y la implementación de tecnologías para las pruebas de la COVID-19. La iniciativa tiene cuatro programas: RADx Tech, Plataformas de tecnología avanzada RADx, Poblaciones desatendidas RADx y RADx Radical. Esta aprovecha la Red de Investigación de Tecnología de Punto de Atención de los NIH existente. La iniciativa RADx se asocia con las agencias federales, incluida la Oficina del Subsecretario de Salud, el Departamento de Defensa, la Autoridad de Investigación y Desarrollo Biomédico Avanzado, y la Administración de Alimentos y Medicamentos de los EE. UU. Obtenga más información sobre la iniciativa RADx y sus programas en: https://www.nih.gov/radx.

Acerca del Instituto Nacional de Salud Infantil y Desarrollo Humano Eunice Kennedy Shriver (NICHD): El NICHD lidera la investigación y la capacitación para comprender el desarrollo humano, mejorar la salud reproductiva, mejorar la vida de niños y adolescentes, y optimizar las habilidades para todos. Si desea más información, visite https://espanol.nichd.nih.gov.

Acerca de los Institutos Nacionales de la Salud (NIH): NIH, la agencia de investigación médica de los EE. UU., incluye 27 institutos y centros, y es un componente del Departamento de Salud y Servicios Humanos de los EE. UU. NIH es la principal agencia federal que realiza y apoya investigaciones médicas básicas, clínicas y traslacionales, y que investiga las causas, los tratamientos y las curas para enfermedades comunes y raras. Para obtener más información sobre los NIH y sus programas, visite https://salud.nih.gov.

FUENTE Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institutes of Health (NIH)

DALLAS, Dec. 28, 2020 /PRNewswire/ — Robin Autopilot USA, a leader in robotic mowing technology, has entered into a partnership with a brand under the Weed Man USA ownership umbrella, TurfBot Mowing. This partnership will introduce the benefits of robotic mowing to a growing portion of the North American lawn maintenance and landscaping market.

Under the new partnership, TurfBot franchises will offer robotic mowing services powered by Robin’s industry-leading technology. TurfBot franchises will have access to all of the tools and resources available through the Robin platform, including patented products, proprietary software, e-learning and training services, and marketing collateral.

Ranked as the eighth-largest company on the 2020 Lawn & Landscape Top 100, based on 2019 revenue, Weed Man has provided high-quality lawn care services for 50 years. The company expanded into the robotic mowing business when it launched TurfBot in 2018 to test the concept, recognizing the benefits of offering battery-powered and emissions-free robotic mowing services to customers. TurfBot currently operates in three locations and plans for aggressive expansion plans in 2022.

«We are proud to partner with Weed Man, which has a long and outstanding history as a pioneer and leader in the North American market for lawn care services,» said Logan Fahey, chief executive officer of Robin Autopilot. «We are creating a strong new force in the lawn and landscaping market that will help both of our companies continue our growth as we provide more customers with the opportunity to adopt robotic mowing technology.»

«Robin Autopilot was the obvious choice for us in our search for a partner with cutting-edge technology and expertise that would help us grow in the exciting robotic mowing industry,» said Jennifer Lemcke, chief executive officer of Weed Man. «We believe robotic mowing has a bright future, and we look forward to working with Robin to continue the transformation of the lawn care industry through the wide-ranging environmental and economic benefits of this new technology.»

About Robin Autopilot  
Robin Autopilot’s software platform provides solutions to enable landscapers to begin offering robotic mowing to their customers by providing software to manage their fleet and jobs, training and educational materials for their staff and customers, marketing collateral to expand their customer base, and finally, innovative products to simplify the installation and management of robotic mowers.  Robotic mowers are battery-powered, programmable, and energy- and cost-efficient. They can be used daily to keep a lawn trimmed to a precise length, resulting in a more attractive landscape with pollution-reducing benefits equivalent to replacing two family cars with electric vehicles. This allows landscapers and lawn maintenance crews to deliver a more reliable and eco-friendly lawn care solution than traditional gas-powered mowing and also results in a healthier lawn. The automated mowers also offer significant relief for landscape service providers who are challenged by a lack of available workforce in many markets. 

About Weed Man 
Based in Oshawa, Ontario, Canada, Weed Man has provided high-quality lawn care services since 1970. During that time, the company has grown from its Canadian roots into an international network of more than 300 locally owned and operated franchises providing services that produce lush green lawns for homeowners in Canada, the United States and the United Kingdom. Weed Man’s environmentally responsible lawn care programs and services focus on a well-balanced, high-quality fertilization program first, which in turn produces the thickest, healthiest lawn possible. From lawn fertilization to weed control, integrated pest management, and everything in between, Weed Man has a lawn care program for every lawn.

For more information, contact:
Ellen Bruno, VP, Operations 
574-524-0364 
ellen@robinautopilot.com 

 

View original content:http://www.prnewswire.com/news-releases/robin-autopilot-and-weed-man-form-partnership-to-strengthen-both-companies-positions-in-the-rapidly-growing-robotic-mowing-market-301198777.html

SOURCE Robin Autopilot